MCM
BCYC

Monimus Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Monimus Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-93,840
Closed -$664K – 56
2025
Q4 		$664K Buy
93,840
+8,616
+10% +$63.5K 0.44% 50
2025
Q3 		$660K Hold
85,224
– – 0.41% 49
2025
Q2 		$592K Buy
+85,224
New +$679K 0.43% 48

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Monimus Capital Management's BCYC Position: Q1 2026 in Review

Monimus Capital Management sold out of Bicycle Therapeutics (BCYC) in Q1 2026, closing a stake of 93,840 shares — an estimated $664K sold.

Monimus Capital Management first reported a position in BCYC in Q2 2025 and held it in 3 quarters. The position peaked at $664K in Q4 2025. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Monimus Capital Management reported no remaining Bicycle Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Monimus Capital Management sold 93,840 Bicycle Therapeutics shares in Q1 2026, an estimated $664K.
  • Monimus Capital Management first reported a position in Bicycle Therapeutics in Q2 2025 and held it in 3 quarters.
  • Monimus Capital Management's Bicycle Therapeutics position peaked at $664K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Monimus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.